eli lilly & co (LLY:EN Paris)
Transactions by ELI LILLY & CO (LLY) in the last 6 months
Eli Lilly and Company (NYSE:LLY) announces a share repurchase program. Under the program, the Company will repurchase up to $5 billion worth of its shares, at prevailing prices. The repurchases will be made over a period of time. The Board of Eli Lilly and Company have authorized a buyback plan on October 3, 2013. On October 3, 2013, the company initiated a Market Repurchase.
Transition Therapeutics Inc. (TSX:TTH) acquired worldwide development Rights to TT-601 from Eli Lilly and Company (NYSE:LLY) on July 23, 2013. As per the terms of the agreement, Transition Therapeutics will be obligated to pay a low single-digit royalty to Eli Lilly on net sales of TT-601. However, post review of proof-of-concept study data, Eli Lilly has an option to reacquire TT-601 rights. In case Eli Lilly exercises this option, Transition Therapeutics will be eligible ...
|AbbVie Inc||$51.21 USD||-0.14|
|Amgen Inc||$113.98 USD||-0.14|
|AstraZeneca PLC||3,475 GBp||-14.50|
|Takeda Pharmaceutical Co Ltd||¥5,120 JPY||0.00|
|Teva Pharmaceutical Industries Ltd||$40.15 USD||+0.50|
|View Industry Companies|
Post a JobJobs
- Indianapolis, IN | ELI LillyPosted: Sep 26
- Iowa | ELI Lilly and CompanyPosted: Dec 07
- Eagle, ID | ELI LillyPosted: Dec 06
- Tallahassee, FL | ELI LillyPosted: Dec 06